Imfinzi® (durvalumab)

BL 761069

Imfinzi® (durvalumab)

BL 761069

U.S. License Holder:

AstraZeneca UK Ltd.

Date of License:

May-01-2017

Last Update:

Sep-23-2023

approved_indications FDA-Approved Indications

IMFINZI (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:

For the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy;

In combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations;

In combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC);

In combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC);

In combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:17-cv-01028 (D. Del.)

U.S. Patent Nos.
9,402,899 (Immunopotentiative Composition)

Plaintiffs
Bristol-Myers Squibb Co.; E.R. Squibb and Sons LLC; Ono Pharmaceutical Co., Ltd.; Tasuku Honjo

Defendants
AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited

Status
Stipulated Dismissal

BPCIA
N

1:22-cv-00346 (D. Del.)

U.S. Patent Nos.
9,580,505 (Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1) 9,580,507 (Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1) 10,138,299 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,266,594 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,266,595 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,266,596 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,308,714 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,323,092 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling)

Plaintiffs
Bristol-Myers Squibb Co.; E.R. Squibb and Sons, LLC

Defendants
AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited

Status
Stipulated Dismissal

BPCIA
N

1:23-cv-00459 (D. Del.)

U.S. Patent Nos.
9,402,899 (Immuopotentiative Composition)

Plaintiffs
Bristol-Myers Squibb Co.; Dana-Farber Cancer Institute, Inc.; E.R. Squibb and Sons LLC; Ono Pharmaceutical Co., Ltd.; Tasuku Honjo

Defendants
AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited

Status
Consolidated with Lead Case 1:22-cv-00346 (D. Del.); Stipulated Dismissal

BPCIA
N

Related News

Venable’s BiologicsHQ Monthly Injection – July 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 15, 2023
Venable’s BiologicsHQ Monthly Injection – April 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
May 8, 2023
Venable’s BiologicsHQ Monthly Injection – March 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 18, 2022

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha